Gossamer Bio, Inc. GOSS
We are a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension, or PH, including pulmonary arterial hypertension, or PAH, and PH
associated with interstitial lung disease, or PH-ILD. Our goal is to be an industry leader in, and to enhance the lives of patients living with, PH. To accomplish this goal, we have assembled a deeply experienced and highly skilled group of industry veterans, scientists, clinicians and key opinion leaders from leading biotechnology and pharmaceutical companies, as well as leading academic centers from around the world. We intend to maintain a scientifically rigorous and inclusive corporate culture where employees strive to bring improved therapeutic options to patients.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $48.5M | $114.7M | $0 | $0 | — | — | — | — | — | — |
| SG&A | $37.6M | $36.1M | $38.5M | $47.6M | $45.8M | $49.7M | $39.1M | $44.1M | $262.0K | — |
| Total operating expenses | $219.2M | $174.6M | $183.8M | $218.6M | $216.1M | $234.0M | $186.1M | $149.0M | $6.7M | — |
| Operating income | -$170.7M | -$59.9M | -$183.8M | -$218.6M | -$216.1M | -$234.0M | -$186.1M | -$149.0M | -$6.7M | — |
| Interest expense | $11.0M | $11.5M | $13.5M | $13.9M | $19.4M | $12.7M | $1.9M | $12.0K | — | — |
| Pre-tax income | -$170.5M | -$55.6M | -$179.8M | -$229.4M | -$234.0M | -$243.4M | -$180.3M | -$147.0M | $6.8M | — |
| Income tax | $88.0K | $893.0K | $0 | $0 | — | — | $0 | $0 | $0 | — |
| Net income | -$170.4M | -$56.5M | -$179.8M | -$229.4M | -$234.0M | -$243.4M | -$180.3M | -$147.0M | -$6.8M | — |
| EPS, basic | -0.75 | -0.25 | -1.18 | -2.71 | -3.13 | -3.55 | -3.29 | — | — | — |
| EPS, diluted | -0.75 | -0.25 | -1.18 | -2.71 | -3.13 | -3.55 | -3.29 | -22.59 | -0.74 | — |
| Shares, diluted (wtd. avg.) | 228.5M | 226.2M | 152.6M | 84.6M | 74.8M | 68.5M | 54.7M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $37.7M | $46.1M | $32.1M | $112.0M | $183.5M | $486.6M | $135.1M | $105.4M | $315.0K | $60.0K |
| Short-term investments | $109.1M | $248.4M | $264.3M | $143.7M | $141.8M | $26.6M | $266.7M | $123.4M | — | — |
| Receivables | $12.2M | $5.3M | $0 | — | — | — | — | — | — | — |
| Total current assets | $167.6M | $309.9M | $306.5M | $261.9M | $331.8M | $522.3M | $409.3M | $232.0M | — | — |
| Property, plant and equipment | $64.0K | $10.0K | $1.6M | $4.0M | $5.3M | $5.5M | $5.4M | $3.2M | — | — |
| Total assets | $172.2M | $315.3M | $311.9M | $272.4M | $343.7M | $539.4M | $426.6M | $239.4M | — | — |
| Accounts payable | $6.0M | $2.3M | $5.5M | $1.5M | $3.2M | $7.5M | $956.0K | $2.2M | — | — |
| Short-term debt | — | $0 | $11.6M | $11.6M | $0 | — | — | — | — | — |
| Total current liabilities | $63.4M | $45.0M | $51.6M | $49.2M | $39.9M | $38.6M | $36.9M | $20.4M | — | — |
| Long-term debt | — | $0 | $814.0K | $12.0M | $29.1M | $28.7M | $28.5M | — | — | — |
| Total liabilities | $295.0M | $285.8M | $249.1M | $260.4M | $222.2M | $218.7M | $74.1M | $21.1M | — | — |
| Retained earnings | -$1.44B | -$1.27B | -$1.21B | -$1.03B | -$811.5M | -$577.5M | -$334.2M | -$153.9M | — | — |
| Total equity | -$122.8M | $29.5M | $62.8M | $12.1M | $121.5M | $320.7M | $352.5M | -$120.1M | -$6.9M | -$123.0K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$171.3M | -$3.5M | -$159.2M | -$187.0M | -$188.9M | -$176.4M | -$144.8M | -$51.0M | -$5.7M | — |
| Depreciation and amortisation | $24.0K | $833.0K | $1.6M | $1.8M | $1.7M | $1.4M | $917.0K | $297.0K | $0 | — |
| Stock-based compensation | $10.6M | $20.6M | $28.5M | $42.6M | $32.0M | $38.7M | $20.8M | $30.9M | $32.0K | — |
| Capital expenditure | $79.0K | $0 | $0 | $410.0K | $1.5M | $1.5M | $3.0M | $3.5M | — | — |
| Investing cash flow | $156.4M | $29.0M | -$111.0M | -$1.0M | -$117.4M | $215.3M | -$147.1M | -$144.7M | — | — |
| Financing cash flow | $6.4M | -$11.5M | $190.2M | $117.1M | $3.3M | $312.5M | $321.6M | $300.9M | $6.0M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001728117-26-000052.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $0 | $0 | $114.7M | $48.5M |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | — | -$6.8M | -$147.0M | -$180.3M | -$243.4M | -$234.0M | -$229.4M | -$179.8M | -$56.5M | -$170.4M |
Recent filings and events
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Charter or fiscal year changed Item 5.03
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Charter or fiscal year changed Item 5.03
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Material agreement signed Item 1.01
- Material agreement terminated An agreement that mattered has ended. Often the other half of a deal that fell through. Item 1.02
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |